Company intelligence / Profile preview

Curtana Pharmaceuticals

Austin, Texas, United Statescurtanapharma.com ↗

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Curtana Pharmaceuticals develops highly targeted small molecule therapies for brain cancers. Its lead candidate CT‑179 targets OLIG2-expressing cancer stem cells and has shown significant survival benefit in animal models. CT‑179 has received FDA Orphan Drug designation for malignant gliomas and Rare Pediatric Disease Designation for medulloblastoma. As of mid–2021/2022, the company was preparing to enter clinical trials with CT‑179.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

CT-179

Partnerships

Catalent – development and manufacturing agreement for CT‑179 tablet formulation and CGMP manufacturing support.

Beyond the preview

Go deeper on Curtana Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curtana Pharmaceuticals.